Pharmac will ease restrictions on at least nine cancer drugs, including keytruda for the treatment of advanced melanoma, to reduce hospital visits...
Myeloma NZ
Kiwis with incurable blood cancer set to receive newly reimbursed treatment option
New Zealanders living with the incurable blood cancer, multiple myeloma, are set to gain access to a new treatment option following the decision by...
New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and...
Article of the week: Managing haematology and oncology patients during the COVID-19 pandemic
Myeloma Australia's Medical and Scientific Advisory Group (MSAG) presents the article of the week. The article from Australia’s National Centre for...
Information About COVID-19 for Myeloma Patients
COVID-19, short for coronavirus disease 2019, is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is...
Coronavirus in NZ: How to self-isolate – Kiwi diagnosed with cancer shares advice
A Kiwi diagnosed with cancer has shared advice on how to self-isolate while living with others and what precautions immunocompromised people should...
National Research Cancer Institute UK Confirms Benefit Molecular Profiling in Multiple Myeloma
ROTTERDAM, Netherlands and SAN DIEGO, March 17, 2020 /PRNewswire/ -- SkylineDx shares research showing that multiple myeloma (blood cancer) patients...
Myeloma and the Coronavirus
With rising community concern about the novel coronavirus or COVID-19, Myeloma Australia would like to provide the following information sheet...
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
There is an increasing clinical interest in the measure and achievement of minimal residual disease (MRD) negativity in the bone marrow of Multiple...
Multiple Myeloma Research Review
Highlights include: Daratumumab + standard care in newly diagnosed MM OS with daratumumab + bortezomib/melphalan/prednisone in newly diagnosed MM...
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy for people with multiple myeloma has been successfully created and tested in cell-based experiments and a mouse model, a...
Organ responses with daratumumab therapy in previously treated AL amyloidosis
Immunoglobulin light chain amyloidosis (AL amyloidosis) involves deposition of abnormally folded light chains into a wide range of tissues causing...